Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Mar 09, 2022 10:42am
119 Views
Post# 34499299

RE:RE:Is this a game changer

RE:RE:Is this a game changer

We'd need to see the full posters. It's in the same vein as stuff we've seen before but as you say an extension to that. To be honest it doesn't move the needle much for me. They've been hitting home runs with the preclinical and this continues that.

The stem-like cells work is exciting but it's difficult to see how that translates into an observable response in these early trials they are doing with this particular patient group. In other types of trials that intervene at other times in the treatment process it could certainly make a difference. Having said that, most of the time we think of progression in our trial as tumours growing but it can also occur when new tumours form. I guess there is potential there for better PFS if you are stopping new tumours forming, as long as the pre-existing tumours aren't growing.

You can see why they are still very positive about this program. It can happens but it's hard to believe all this doesn't translate into some human efficacy

SPCEO1 wrote: It is defintely not yesterday's news reheated - it is new info and it does clearly suggest that TH-1902 inhibits tumor growth. It sounds like the study done was a step above the intiial pre-clinical work but I will let our science team tell us how meaningful this data is. 
 

Trogarzon wrote:
Is this new demonstrative data increasing probaility of POC in humans otherwise it's interesting to advance science but what's in it for shareholders can someone comment on this news. It feels like yesterday's news reheated...




<< Previous
Bullboard Posts
Next >>